---
title: "AMM (marketing authorisation) · Treats"
description: "The AMM is the marketing authorisation a veterinary medicine needs before it can be sold, granted in France by the ANMV or at EU level by the European Commission."
url: https://www.treats.vet/en/glossary/amm/
lang: en-GB
updated: 2026-11-07
---

[Glossary](https://www.treats.vet/en/glossary/)

# AMMmarketing authorisation

The AMM is the marketing authorisation a veterinary medicine needs before it can be sold, granted in France by the ANMV or at EU level by the European Commission.

Since 28 January 2022, a veterinary marketing authorisation is valid for an unlimited period (article 5 of Regulation (EU) 2019/6). It sets the medicine’s [SPC](https://www.treats.vet/en/glossary/rcp/) and its prescription status.

## Sources

* [Regulation (EU) 2019/6 (EUR-Lex)](https://eur-lex.europa.eu/legal-content/FR/TXT/HTML/?uri=CELEX:32019R0006)

 Checked on 7 November 2026 · by [Amir Davies](https://www.treats.vet/en/about/amir-davies/)

## See also

* [RCP](https://www.treats.vet/en/glossary/rcp/) The RCP, or SPC (summary of product characteristics), is the official document attached to a veterinary marketing authorisation that sets out the medicine’s composition, target species, indications, dosage, contraindications and withdrawal periods (article 35 of Regulation (EU) 2019/6).
* [Cascade](https://www.treats.vet/en/glossary/cascade/) The cascade is the derogation that lets a vet, exceptionally and on their own responsibility, prescribe a medicine outside its marketing authorisation when no authorised product exists for the species and condition (articles 112 to 114 of Regulation (EU) 2019/6).
* [ANMV](https://www.treats.vet/en/glossary/anmv/) The ANMV is the department of ANSES, based in Fougères, that acts as France’s competent authority for veterinary medicines.